Spinal Muscular Atrophy Market, By Disease Type (Type I, Type II, Type III, and Type IV), By Age (Infant and Adult), By Treatment (Drug Therapy and Gene Therapy) and By Region - Trends, Analysis and Forecast till 2034

Owing to several current studies

Although there isn't a cure for SMA at the moment, research is being done to identify potential new treatments. To control the symptoms and provide the best quality of life possible for those with SMA, treatment and support are available. Nusinersen, also known as Spinraza, was the first medication to be approved by the U.S. Food and Drug Administration (FDA) in December 2016 for the treatment of SMA in adults and children, including newborns. August 2018: Mestinon (pyridostigmine), a medication licensed for myasthenia gravis, is being studied as a potential treatment for fatigue in patients with spinal muscular atrophy (SMA) types II, III, and IV as part of a phase II clinical research.

An increase in spinal muscular atrophy cases

Additionally, over the course of the forecast period, rising numbers of ongoing clinical trial studies, growing funding for research and development from government and various healthcare regulatory bodies, and rising cases of spinal muscular atrophy globally are some of the key factors anticipated to propel growth in the global spinal muscular atrophy market.